COVID-19 pandemic has resulted in short-term and long-term health, economic, and social repercussions since its outbreak in December 2019. More research is required to determine how the pandemic impacts various segments of the population. Preliminary research suggests that COVID-19 impacts menstrual cycles in different ways. The primary objective of this study was to assess alterations in menstrual cycles among women in the United Arab Emirates (UAE) following the pandemic. A cross-sectional online study was conducted between October 2022 and January 2023, enrolled 439 UAE women using the snowball technique. The Menstrual Symptom Questionnaire and Depression Anxiety Stress Scale were used to evaluate menstrual symptoms and assess depression and stress levels, respectively. The findings showed a significant increase in menstrual symptoms with both higher mean of pads usage per day and use of pain medication during menses after COVID-19 with a -value <0.001. Moreover, women reported higher levels of psychological distress after COVID-19 (Beta = 1.47). The findings show that COVID-19 affected the menstrual symptoms in women, reflected by higher pads usage per day, bleeding days, and frequency of pain medication intake during menses. Furthermore, higher stress levels were reported in the post-COVID-19 period.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/09603123.2024.2337828 | DOI Listing |
Minerva Obstet Gynecol
January 2025
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Introduction: Polycystic ovary syndrome (PCOS) is a heterogeneous endocrine-metabolic syndrome mainly characterized by ovarian dysfunction, which is only one manifestation of a more complex syndrome with a significant systemic impact.
Evidence Acquisition: We review scientific literature on the pathophysiology and diagnosis of PCOS evaluating the most relevant data from original articles, reviews and meta-analyses published until June 2024.
Evidence Synthesis: From a pathophysiological point of view, the concurrence of both metabolic aspects, such as insulin resistance and obesity, and hormonal alterations, such as hyperandrogenemia, might produce the most relevant clinical signs and/symptoms of this syndrome, for instance menstrual irregularities, hair loss, acne and hirsutism.
CVIR Endovasc
January 2025
Department of Radiology, Graduate School of Medicine, Juntendo University, 2-1-1 Hongo Bunkyo-Ku, Tokyo, 113-8421, Japan.
Background: Classifying uterine fibroid using the International Federation of Gynecology and Obstetrics (FIGO) classification system assists treatment decision-making and planning. This study aimed to study whether different fibroid locations influence clinical outcomes following uterine artery embolization (UAE).
Methods: This is a retrospective cohort study of patients who underwent UAE for symptomatic uterine fibroid between December 2016 and January 2023 at our hospital.
Naunyn Schmiedebergs Arch Pharmacol
January 2025
Faculty of Medicine, Cairo University, Cairo, Egypt.
Acne vulgaris (AV) is a common chronic inflammatory skin disorder that commonly lasts from adolescence to adulthood and has serious social and psychological consequences. Current treatments typically use antibacterial drugs, which contributes to the rise in antibacterial drug resistance. Spironolactone, a potassium-sparing diuretic with anti-androgen effects, has been used off-label to treat acne by lowering sebum production.
View Article and Find Full Text PDFJ Atten Disord
January 2025
University of Amsterdam, The Netherlands.
Objective: Stimulant medications are the primary pharmacological intervention for ADHD, yet our understanding of how sex and gender impact stimulant treatment outcomes remains limited. Clinical guidelines do not differ for female and male individuals despite possible sex and gender-related differences in effectiveness, adverse events, and pharmacokinetics. This theoretical framework identifies five key knowledge gaps relating to sex and gender effects in stimulant treatment.
View Article and Find Full Text PDFFront Endocrinol (Lausanne)
January 2025
Reproductive Medicine Center, Sichuan Provincial Women's and Children's Hospital, The Affiliated Women's and Children's Hospital of Chengdu Medical College, Chengdu, China.
Background: Growth hormone (GH) could improve the outcomes of fertilization and embryo transfer (IVF-ET) in patients with decreased ovarian reserve (DOR), but which age group will benefit the most has remained controversial. This study aims to explore the outcome of IVF-ET among differently aged patients with DOR treated with GH.
Methods: A total of 846 patients with DOR undergoing IVF-ET from May 2018 to June 2023 at the Reproductive Medicine Center of Sichuan Provincial Women's and Children's Hospital were prospectively enrolled.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!